Mylan And Perrigo: Why Everybody Wins
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan can refocus on other deal opportunities, and Chairman Robert Coury emphasizes it is "well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified."
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.